Exploring the Role of Biosimilars in Optimizing Treatment of Retinal Diseases

Understanding Biosimilar Clinical Trials

Peter Kaiser, MD

Show Description +

Peter Kaiser, MD, explains why biosimliar clinical trials look at BCVA and CRT at 4 and 8 weeks, respectively, compared to originator biologics.

Posted: 4/14/2023

Keywords:

Biogen

•

biosimilars

•

Clinical Trials

•

Best Corrected Visual Acuity, BCVA

•

Central Retinal Thickness, CRT

•

biologics

Up Next

Name: Understanding Biosimilar Clinical Trials
Uploaded: 2023-04-14T21:04:18+00:00
Description: Peter Kaiser, MD, explains why biosimliar clinical trials look at BCVA and CRT at 4 and 8 weeks, respectively, compared to originator biologics.

Ranibizumab-nuna: Review of Clinical Trial Data

Neil Bressler, MD

A Deeper Look at Clinical Trial Outcomes

David Brown, MD; Diana Do, MD; Peter Kaiser, MD; Neal Bressler, MD

Adopting Bioimilars: Practical Considerations

David Brown, MD

Biosimilars: Health Economic Aspects

David Brown, MD

Biosimilars: Learning from Other Parts of Medicine

Diana Do, MD

What Does the Conversation Sound Like?

David Brown, MD

The Current Treatment Paradigm in nAMD

Diana Do, MD

Undertreatment of nAMD and Implications for LongTerm Vision

David Brown, MD; Diana Do, MD; Peter Kaiser, MD; Neal Bressler, MD

What Is a Biosimilar?

Peter Kaiser, MD

Biosimilars: Impact on Cost

Peter Kaiser, MD

Back to All Videos

Understanding Biosimilar Clinical Trials

Peter Kaiser, MD

Peter Kaiser, MD, explains why biosimliar clinical trials look at BCVA and CRT at 4 and 8 weeks, respectively, compared to originator biologics.

Posted: 4/14/2023

Keywords:

Biogen

•

biosimilars

•

Clinical Trials

•

Best Corrected Visual Acuity, BCVA

•

Central Retinal Thickness, CRT

•

biologics

Resources

Biosimilars in Retinal Disease Management

View Resource

About Biogen

One of the world’s first global biotechnology companies, Biogen, was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Biogen is commercializing biosimilars and transforming the standard of care for patients in several areas of high unmet need.

Follow Biogen